ArticleJournal of advanced research2023
Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis.
Article in Journal of advanced research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 101 citations in OpenAlex.
- Theabrownin Alleviates Alcoholic Liver Disease in Mice by Improving Gut Microbiota and Tryptophan Metabolism.Molecular nutrition & food research · 2026Article
- Polyphenols as Systems Modulators of the Gut-Brain-Liver Axis: A Narrative Review of Neuro-Metabolic and Immunomodulatory Networks.Molecular nutrition & food research · 2026Review
- Akkermansia: A Potential Target for Natural Botanicals in Treatment of Nonalcoholic Fatty Liver Diseases.Chinese journal of integrative medicine · 2026Review
- Lactoferrin alleviates non-alcoholic steatohepatitis via remodeling gut microbiota to regulate serotonin-related pathways.Journal of advanced research · 2026Article
- Mechanistic insights and evidence-based management of metabolic dysfunction-associated steatotic liver disease (MASLD; formerly NAFLD) through combined diet and exercise interventions: an evidence-based narrative review.Journal of clinical biochemistry and nutrition · 2026Review
- Gut Microbiota-Mediated Modulation of Intestinal Serotonin by Tea Polyphenols: Potential Mechanisms and Implications for Metabolic Health.Nutrients · 2026Review
- Theabrownin from Dark Tea Attenuates Age-Related Cognitive Decline in Naturally Aged Mice by Modulating Gut Microbiota and Metabolites.Foods (Basel, Switzerland) · 2026Article
- Impact of processing techniques on chemical compositions and sensory attributes across five types of Yunnan large-leaf teas.Food chemistry: X · 2026Article
- Perfluorooctane sulfonic acid impairs spermatogenesis via the liver-gut microbiota-testis axis: a central role of chenodeoxycholic acid metabolism.Journal of advanced research · 2026Article
- Si-Wu-Tang Targets Microbiota Homeostasis and Intestinal Mucosal Barriers to Provide Protection Against MASLD by FavoringPharmaceuticals (Basel, Switzerland) · 2026Article
- Ershiwuwei Shanhu Pill ameliorates cognitive impairment in Alzheimer's disease mice by remodeling gut microbiota and host serum metabolites.Frontiers in aging neuroscience · 2026Article
- The gut-liver axis: microbial mechanisms and therapeutic implications in MAFLD.Frontiers in cellular and infection microbiology · 2026Review
- Polygonatum odoratum extract ameliorates acetaminophen-induced acute liver injury by modulating the gut-liver axis and remodeling microbial and ceramide metabolism to suppress hepatic ferroptosis: insights from multi-omics.Frontiers in pharmacology · 2026Article
- The effects of a composition of ginseng polysaccharides andFrontiers in veterinary science · 2026Article
- Herbal medicines modulate gut microbiota in metabolic diseases: a review.Frontiers in microbiology · 2026Review
- Article
- Targeting the gut microbiota: the application and prospects of probiotics, fecal microbiota transplantation, and natural products in MASLD.Frontiers in nutrition · 2026Review
- Intestinal-related substances in obesity regulation: A comprehensive review.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Protective effects and metabolomics analysis of dihydromyricetin on cyclophosphamide-induced hepatotoxicity in mice.Pharmaceutical science advances · 2025Article
- Akkermansia muciniphila: a microbial guardian against oxidative stress-gut microbiota crosstalk and clinical prospects.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-alcoholic fatty liver disease (NAFLD) with obesity seriously threats public health. Our previous studies showed that dark tea had more potential on regulating lipid metabolism than other teas, and theabrownin (TB) was considered to be a main contributor to the bioactivity of dark tea.
objectivesThis in vivo study aims to reveal the effects and molecular mechanisms of TB on NAFLD and obesity, and the role of the gut-liver axis is explored.
methodsThe histopathological examinations, biochemical tests, and nuclear magnetic resonance were applied to evaluate the effects of TB on NAFLD and obesity. The untargeted metabolomics was used to find the key molecule for further exploration of molecular mechanisms. The 16S rRNA gene sequencing was used to assess the changes in gut microbiota. The antibiotic cocktail and fecal microbiota transplant were used to clarify the role of gut microbiota.
resultsTB markedly reduced body weight gain (67.01%), body fat rate (62.81%), and hepatic TG level (51.35%) in the preventive experiment. Especially, TB decreased body weight (32.16%), body fat rate (42.56%), and hepatic TG level (42.86%) in the therapeutic experiment. The mechanisms of action could be the improvement of fatty acid oxidation, lipolysis, and oxidative stress via the regulation of serotonin-related signaling pathways. Also, TB increased the abundance of serotonin-related gut microbiota, such as Akkermansia, Bacteroides and Parabacteroides. Antibiotics-induced gut bacterial dysbiosis disrupted the regulation of TB on serotonin-related signaling pathways in liver, whereas the beneficial regulation of TB on target proteins was regained with the restoration of gut microbiota.
conclusionWe find that TB has markedly preventive and therapeutic effects on NAFLD and obesity by regulating serotonin level and related signaling pathways through gut microbiota. Furthermore, gut microbiota and TB co-contribute to alleviating NAFLD and obesity. TB could be a promising medicine for NAFLD and obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.